TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer

BACKGROUND: Recombinant interleukin-2 (IL-2, aldesleukin) is an approved cancer immunotherapy but causes severe toxicities including cytokine storm and vascular leak syndrome (VLS). IL-2 promotes antitumor function of IL-2Rβ/γ(+) natural killer (NK) cells and CD8(+), CD4(+) and gamma delta (γδ) T ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosen, David B, Kvarnhammar, Anne Månsson, Laufer, Burkhardt, Knappe, Thomas, Karlsson, Jens Jakob, Hong, Enping, Lee, Yu-Chi, Thakar, Dhruv, Zúñiga, Luis Alejandro, Bang, Kathy, Sabharwal, Simran Singh, Uppal, Karan, Olling, Janne Damm, Kjaergaard, Kristian, Kurpiers, Thomas, Schnabel, Meike, Reich, Diana, Glock, Philipp, Zettler, Joachim, Krusch, Mathias, Bernhard, Ana, Heinig, Stefan, Konjik, Valentino, Wegge, Thomas, Hehn, Yvonne, Killian, Steffen, Viet, Laura, Runz, Josefine, Faltinger, Frank, Tabrizi, Mohammad, Abel, Kristin Laura, Breinholt, Vibeke Miller, Singel, Stina M, Sprogøe, Kennett, Punnonen, Juha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274542/
https://www.ncbi.nlm.nih.gov/pubmed/35817480
http://dx.doi.org/10.1136/jitc-2022-004991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274542/
https://www.ncbi.nlm.nih.gov/pubmed/35817480
http://dx.doi.org/10.1136/jitc-2022-004991

Ejemplares similares